ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharmaceuticals is well positioned by a 3Q 2026 earnings beat, with sales of $290.8M and non-GAAP EPS of $2.70, both ahead of expectations, driven by stronger Generics revenue and lower SG&A and R&D spending. Although Cortrophin revenue came in below guidance and FY 2026 Cortrophin sales guidance was reduced to $480M-$500M, management framed the issue as a conversion bottleneck rather than weaker demand, pointing to doubled new gout cases QoQ and a 67% increase in gout prescribers QoQ. The outlook is further supported by Iluvien’s better-than-expected $22.3M sales, improved FY 2026 guidance of $80M-$85M, and the proposed Egetis Therapeutics acquisition, which adds a first-and-only ultra-rare disease asset with >$300M peak sales potential and reinforces the rare disease transition.

ANI Pharmaceuticals is exposed to meaningful execution risk because unforeseen clinical, regulatory, manufacturing, or commercial setbacks could disrupt key growth drivers, especially Purified Cortrophin Gel and Iluvien. Its outlook is further pressured by the possibility that the Alimera integration could prove more difficult than expected or that management may struggle to complete attractive future deals, which would limit strategic flexibility. In addition, worsening pricing and competitive pressures in the generics industry could weigh on margins and offset gains from its Rare Disease and Brands businesses, leaving overall fundamentals vulnerable.